CRYO-CELL INTERNATIONAL, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.726 USD | -2.39% |
|
+1.12% | +51.77% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Weaknesses
- The company has insufficient levels of profitability.
- With an expected P/E ratio at 298 and 74.5 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +51.77% | 72.45M | - | ||
| +18.22% | 83.07B | C+ | ||
| -29.96% | 70.89B | B- | ||
| +3.59% | 28.32B | C+ | ||
| -7.92% | 17.73B | B | ||
| +2.07% | 17.43B | A- | ||
| +0.47% | 15.64B | A- | ||
| +6.85% | 13.46B | B- | ||
| +8.40% | 12.82B | A- | ||
| +69.03% | 12.69B | C- |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
- Stock Market
- Equities
- CCEL Stock
- Ratings Cryo-Cell International, Inc.